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Stability of Extemporaneously Prepared Sodium Benzoate Oral Suspension 
Abstract 
The stability of extemporaneously prepared sodium benzoate oral suspension in cherry syrup and Ora-
Sweet was studied. Oral solutions of 250-mg/mL sodium benzoate were prepared in either cherry syrup or 
Ora-Sweet. To a beaker, 50 grams of Sodium Benzoate Powder USP was dissolved and filtered, the 
solution was divided equally into two parts, and each aliquot was added into two separate calibrated 
100-mL amber vials. In the first vial, cherry syrup was added to make a final volume of 100 mL. In the 
second vial, Ora-Sweet was added to give a final volume of 100 mL. This process was repeated to prepare 
three solutions of each kind and all were stored at room temperature. A 250-µL sample was withdrawn 
immediately after preparation and again at 7, 14, 28, 60, and 90 days for each sample. At each time point, 
further dilution was made to an expected concentration of 0.25 mg/mL with sample diluent, and the 
samples were assayed in triplicate by stability-indicating high-performance liquid chromatography. 
Stability was defined as the retention of at least 90% of the initial concentration. At least 92% of the initial 
concentration of sodium benzoate in cherry syrup and at least 96% of the sodium benzoate in Ora-Sweet 
remained throughout the 90-day study period. There were no detectable changes in color and no visible 
microbial growth in any sample. Extemporaneously compounded suspensions of sodium benzoate in 
cherry syrup or Ora-Sweet were stable for at least 90 days when stored in a 4-oz amber plastic bottle at 
room temperature in reduced lighting. 
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INTRODUCTION
Urea cycle disorders (UCDs) are genetic 
disorders that result from defective metabo­
lism of nitrogenous waste produced by 
the breakdown of nitrogen-containing 
molecules such as proteins.^ A mutation or 
deficiency in any or all essential enzymes 
and cofactors in the urea cycle result in 
accumulation of ammonia as well as precur­
sor metabolites in the blood.’^ Depending on 
the severity of the mutation, sjnnptoms may 
include vomiting, lethargy, permanent brain 
damage, coma, and death.^
Individuals with UCDs consume a low- 
protein diet and are often treated with
nitrogen ammonia scavengers. One sub­
stance used to remove nitrogenous waste is
ABSTRACT sodium benzoate. Sodium benzoate is the
The stability of extemporaneously prepared sodium benzoate oral suspension 
in cherry syrup and Ora-Sweet was studied. Oral solutions of 250-mg/mL 
sodium benzoate were prepared in either cherry syrup or Ora-Sweet. To a 
beaker, 50 grams of Sodium Benzoate Powder USP was dissolved and filtered, 
the solution was divided equally into two parts, and each aliquot was added 
into two separate calibrated 100-mL amber vials. In the first vial, cherry syrup 
was added to make a final volume of 100 ml. In the second vial, Ora-Sweet was 
added to give a final volume of 100 ml. This process was repeated to prepare 
three solutions of each kind and all were stored at room temperature. A 250-p.L 
sample was withdrawn immediately after preparation and again at 7,14,28,60, 
and 90 days for each sample. At each time point, further dilution was made to 
an expected concentration of 0.25 mg/mL with sample diluent, and the 
samples were assayed in triplicate by stability-indicating high-performance 
liquid chromatography. Stability was defined as the retention of at least 90% of 
the initial concentration. At least 92% of the initial concentration of sodium 
benzoate in cherry syrup and at least 96% of the sodium benzoate in Ora-Sweet 
remained throughout the 90-day study period. There were no detectable 
changes in color and no visible microbial growth in any sample. 
Extemporaneously compounded suspensions of sodium benzoate in cherry 
syrup or Ora-Sweet were stable for at least 90 days when stored in a 4-oz 
amber plastic bottle at room temperature in reduced lighting.
sodium salt of benzoic acid that conjugates 
with nitrogen-containing glycine to form 
the molecule hippurate. Hippurate can 
then be excreted by the kidneys, thereby 
removing nitrogenous waste from the 
bloodstretim.^ One mole of hippurate con­
tains, and allows for removal of, one mole of 
nitrogenous waste.®
Currently, Sodium Benzoate USP is only 
available as a powder. UCD affects adults, 
children, and newborns. All subsets of 
patients can have difficulty taking oral 
tablets or capsules, therefore, a liquid for­
mulation is often used. While the efficacy 
of liquid formulations of sodium benzoate 
has been established, currently, there is no 
data available on the stability of sodium 
benzoate in suspension. The purpose of this 
study was to evaluate the 90-day stability 
of sodium benzoate in either cherry or Ora- 
Sweet syrup.
METHODS 
SAMPLE PREPARATION
The authors’ affiliations are: Julia R. Atkins, PharmD Student, 
Melinda E, Lull, Associate Professor of Pharmaceutical Sciences, 
and David J. Hutchinson, Associate Professor of Pharmacy 
Practice, Wegmans School of Pharmacy, St. John Fisher College, 
Rochester, New York; Andrew S. Decker, Clinical/Staff Pharmacist, 
Golisano Children’s Hospital, University of Rochester Medical 
Center, Rochester, New York.
Sodium benzoate 250-mg/mL solu­
tions were compounded (formulation 
and method of preparation shown below) 
using Sodium Benzoate Powder USP (Lot 
MKBL2285V; Sigma-Aldrich, St. Louis, 
Missouri). To a beaker, 50 grams of the 
sodium benzoate powder was added to 
100 mL of sterile water. Once the powder 
was fully dissolved and filtered, the solu-
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tion was divided equally into two parts, 
and each aliquot was added into separate 
calibrated 100-mL amber, oval prescrip­
tion vials with child-resistant closures 
(Total Pharmacy Supply, Arlington, Texas). 
Four liters of cherry syrup was prepared by 
adding 4 mL of cherry flavoring to Simple 
Syrup NF (sucrose 85%, purified water, 
0.01% citric acid, methylparaben 0.1%). In 
the first vial, prepared cherry syrup (Lot 
114729:02; University of Rochester Medical 
Center Compounding Service, Rochester, 
New York) was added to make a final vol­
ume of 100 mL. In the second vial, Ora- 
Sweet flavored vehicle syrup (Lot 6256027; 
Perrigo, Minneapolis, Minneapolis) was 
added to give a final volume of 100 mL. This 
preparation was repeated in triplicate to 
provide a total of six sodium benzoate 250- 
mg/mL samples (three in cherry syrup and 
three in Ora-Sweet).
The samples were stored at room temper­
ature (23°C to 25°C) in low-light conditions. 
At days 0,7,14,28,60, and 90, a 250-)J.L
Rx
SODIUM BENZOATE 250-MG/ML SUSPENSION
For 200 mL
Sterile water 100 ml
Sodium Benzoate Powder USP 50 g
Cherry syrup or Ora-Sweet qs 200 mL
METHOD OF PREPARATION
1. Calculate the required quantity of each ingredient for the total 
amount to be prepared.
2. Weigh and/or measure each ingredient accurately.
3. Pre-calibrate two 4-ounce, child-resistant, amber bottles to 
100 mL.
4. Rinse all glassware and the final container with sterile water.
5. Place 100 mL of sterile water in a beaker with a magnetic stir-bar 
and place on a stir-plate.
6. Add 50 grams of Sodium Benzoate Powder USP to the sterile water 
and stir until dissolved.
7. Filter and divide the solution in half and place each aliquot in a 
separate pre-calibrated amber bottle from Step 3.
8. Bring each amber bottle to final volume (100 mL) with either 
cherry syrup or Ora-Sweet.
9. Label the bottles and store out of direct light.
Ora-Sweet were achieved. In 
these samples, in addition to 
the sodium benzoate peak at
FORCED DEGRADATION
To test the ability of the 
HPLC method to detect deg­
radation, decomposition of 
sodium benzoate was forced 
by allowing samples of each 
preparation to be exposed to 
three different degradation 
conditions: 1) pH 2 with 1M 
hydrochloric acid, 2) pH of 12 
with 1M sodium hydroxide, 
or 3) 3% hydrogen peroxide. 
Each solution was incu­
bated at 60°C for 24 hours, 
and an additional sample in 
3% hydrogen peroxide was 
placed in direct sunlight for 
7 days. The most pronounced 
degradation was observed 
in the 3% hydrogen peroxide 
sample incubated at 60°C 
for 24 hours. Approximately 
12% degradation in cherry 
syrup and 14% degradation 
of the parent compound in
aliquot from each sample was diluted and filtered using 
a 45-micron filter (syringe filter, nylon,45-micron,
13 mm diameter; CELLTREAT Scientific Products, 
Pepperell, Massachusetts) to an expected concentra­
tion of 0.25 mg/mL with the Scunple diluent (50:50 v/v 
acetonitrile and sterile water). Each of the six samples 
at each time point was assayed in triplicate by high- 
performance liquid chromatography (HPLC).
REVERSE-PHASE HIGH-PERFORMANCE 
LIQUID CHROMATOGRAPHY
Reverse-phase HPLC was performed using a 
Shimadzu model LC2010A instrument (Shimadzu 
Scientific Instruments, Marlborough, Massachusetts) 
with Shimadzu LC Solution Software. The HPLC was 
equipped with a C18 LI 4.6-mm x 15-cm diameter,
5-|im particle column (Ascentis, L x I.D. 15 cm x 4.6 
mm; Supelco, Bellefont, Pennsylvania) maintained at 
25°C and an ultraviolet detector set at 230 nm. The 
mobile phase used was aqueous monobasic potassium 
phosphate (0.020 M) and acetonitrile (30:70, v/v) with 
phosphoric acid delivered at a flow rate of 0.5 mL/ 
minute. The mobile phase was filtered before use. The 
retention time of sodium ben­
zoate was 10.9 minutes.
10.9 minutes, an unidentified 
degradation peak was observed 
at a retention time of 4.8 min­
utes. Approximately 13% deg­
radation in cherry syrup and 
9% degradation in Ora-Sweet 
was achieved with the acidic 
solution. Approximately 10% 
degradation in cherry syrup 
and 10% degradation in Ora- 
Sweet was achieved with the 
sodium hydroxide solution. 
Approximately 7% degrada­
tion in cherry syrup and 10% 
degradation in Ora-Sweet was 
achieved with the 3% hydrogen 
peroxide solution that was in 
direct sunlight for 7 days.
STANDARD SOLUTIONS 
AND STANDARD CURVE
A 250-mg/mL stock solution 
of analytical grade sodium ben­
zoate (Supelco) was prepared 
in 50:50 (v/v) acetonitrile in 
sterile water. Standard samples 
of sodium benzoate were pre­
pared by diluting the stock 
solution with sample diluent 
to 1.0 mg/mL, 0.5 mg/mL,
0.25 mg/mL, 0.125 mg/mL, 
and 0.0625 mg/mL sodium 
benzoate. The standards were 
prepared at day 0, and aliquots 
were frozen at -20°C. Each 
standard wtis assayed in tripli­
cate at every time point of the 
analysis. A standard curve was 
produced by linear regression 
of the peak heights of sodium 
benzoate against sodium ben­
zoate concentration. The stan­
dard curve was linear (average 
r® = 0.985) over the working 
range of concentrations. The 
between-day and within-day 
coefficients of variation for the 
sodium benzoate assay were 
1.92% and 1.15%, respectively.
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SAMPLE 
ANALYSIS
Each of the 
sodium benzo­
ate samples was 
shaken thoroughly 
by hand for approx­
imately 15 seconds 
immediately before 
the assay. Ten 
microliters of each 
sample was assayed 
in triplicate accord­
ing to the HPLC
method described above. The samples were 
visually inspected for color change on each 
day of analysis. Because each commercial 
vehicle contained effective preservatives, 
microbiological testing was not performed.
DATA ANALYSIS
The stability of sodium benzoate in cherry 
syrup and Ora- Sweet was determined by 
calculating the percentage of the initial con­
centration remaining at each time interval 
+/- the standard deviation of replicates. 
Stability was defined as the retention of at 
least 90% of the initial concentration.
RESULTS AND 
DISCUSSION
Currently, Sodium Benzoate USP is only 
available as a powder. The 250-mg/mL 
sodium benzoate suspensions were prepared 
in this study using cherry syrup or Ora- 
Sweet. The results from this study indicate 
that sodium benzoate was chemically and 
physically stable in the two suspensions. 
The RP-HPLC data of the compounded sus­
pensions are summarized in Table 1. Both 
suspensions remained stable (at least 90% 
of initial concentrations) throughout the 
90-day study period. There was no detect­
able change in color and no visible pres­
ence of microbial growth in any samples. 
The bioavailabUity of sodium benzoate 
formulations in the current study has not 
been evaluated. However, the absorption 
and therapeutic effectiveness of a drug in a 
suspension compounded from a powder is
TABLE 1. STABILITY OF SODIUM BENZOATE 250 MG/ML IN TWO VEHICLES AT ROOM TEMPERATURE.
SUSPENSION
ACTUAL INITIAL
DRUG
CONCENTRATION*
(MG/ML)
% INITIAL CONCENTRATION REMAINING*
DAY 7 DAY 14 DAY 28 DAY 60 DAY 90
Cherry syrup 260 + 4.3 95.29 + 2.98 98.81 + 3.40 94.41 ± 4.96 92.57 ± 2.86 92.29 ± 0.65
Ora-Sweet 250 ± 18 97.21 ± 1.93 97.58 ± 1.49 102.32 ± 2.43 96.42 ± 0.74 9704 ± 0.88
“Mean + S.D. of triplicate determinations for each sample
unlikely to differ appreciably from the origi­
nal dosage form.
Before this study, no stability data 
had been published on the preparation 
of sodium benzoate suspension. In the 
absence of stability information from 
documentation, literature, or stability 
tests, t/SP Chapter <795> Pharmaceutical 
Compounding—Nonsterile Preparations^ 
recommends a maximum beyond-use 
date that is “no longer than 14 days or the 
earliest expiration of any ingredient used, 
whichever is shorter, and stored at con­
trolled room temperatures.” The results of 
this study will have a particular benefit for 
infants and children with UCDs, as well as 
others who require a liquid formulation of 
sodium benzoate. In addition, the extended 
stability wUl benefit compounding phar­
macies by reducing workload and increase 
convenience for families, who will be able to 
refiU their prescriptions less frequently.
CONCLUSION
Extemporaneously compounded suspen­
sions of sodium benzoate 250 mg/mL in 
cherry syrup or Ora-Sweet were stable for 
at least 90 days when stored in 4-oz amber, 
plastic bottles at room temperature in low- 
light conditions.
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